As expected, all HER2-amplified cell lines, which do not include the HER2+, yet non-HER2-amplified, MDA-MB-453 breast cancer cell line, were highly responsive to the HER2-targeted TKIs (Table 1 and Supplementary Fig. S1). This evidence concerns the gene ERBB2 and breast carcinoma.